Trials / Completed
CompletedNCT03761849
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 899 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 25 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in participants with manifest Huntington's disease (HD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO7234292 | Intrathecal injection |
| DRUG | Placebo | Intrathecal injection |
Timeline
- Start date
- 2019-01-23
- Primary completion
- 2022-03-24
- Completion
- 2022-03-24
- First posted
- 2018-12-03
- Last updated
- 2024-03-01
- Results posted
- 2023-11-07
Locations
96 sites across 18 countries: United States, Argentina, Australia, Austria, Canada, Chile, Denmark, France, Germany, Italy, Japan, Netherlands, New Zealand, Poland, Russia, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03761849. Inclusion in this directory is not an endorsement.